Methods in cancer research: Assessing therapy response of spheroid cultures by life cell imaging using a cost-effective live-dead staining protocol
View abstract on PubMed
Summary
This summary is machine-generated.We developed a cost-effective live-dead staining method for cancer spheroids, improving therapy response monitoring. This new technique offers a stable, accurate way to assess treatment efficacy in 3D cultures for up to 10 days.
Area Of Science
- Biomedical Engineering
- Cancer Research
- Cell Biology
Background
- Three-dimensional (3D) spheroid cultures are more clinically relevant than 2D models for predicting cancer therapy response.
- Existing live-dead staining methods for spheroids are often costly, toxic, or lack long-term stability.
- Accurate monitoring of therapy response in 3D cancer models is crucial for drug development.
Purpose Of The Study
- To develop a cost-effective and stable live-dead staining protocol for monitoring cancer spheroid therapy response.
- To establish a more accurate method for assessing treatment efficacy in 3D cancer models.
- To validate the protocol using glioblastoma spheroid models.
Main Methods
- Utilized calcein-AM (live cells) and Helix NP™ Blue (dead cells) for live-dead staining in spheroid cultures.
- Employed ICY BioImage Analysis and Z-stacks projection for quantitative viability assessment.
- Visualized spheroid cellular architecture using confocal microscopy.
Main Results
- The developed method enabled stable monitoring of spheroid therapy response for up to 10 days.
- Quantitative viability analysis via image processing proved more accurate than spheroid size measurements.
- Glioblastoma spheroids showed reduced viability after 7-day treatment with temozolomide.
Conclusions
- The novel calcein-AM and Helix NP™ Blue staining method provides a cost-effective, stable, and accurate approach for assessing therapy response in cancer spheroids.
- This versatile method can be adapted for various cancer types and 3D culture models.
- The technique enhances the predictive value of 3D cancer models for therapeutic efficacy evaluation.

